Pancreatic Cancer causes 40,000 deaths each year, with available chemotherapy regimens providing only an average of 6-11 months survival. WashU-born company Accuronix, founded by Dr. William Hawkins and Robert Mach, PhD. (now of the University of Pennsylvania), is taking on this difficult disease by developing novel therapies to selectively target cancer cells, increasing effectiveness and decreasing toxicity.
President and CEO of Accuronix, Dennis Schafer brings more than 30 years experience as a serial Biotech entrepreneur, participating in 12 startups throughout his career.